News & Events
< Back to News Overview
ChemGenex Announces Shareholder Approval to Demerge Verva Pharmaceuticals
29 / 11 / 2007
- ChemGenex to Focus on Late-stage Cancer Portfolio
- Verva Pharmaceuticals merger with Adipogen Pharmaceuticals on track
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced that at the company's Annual General Meeting yesterday it received shareholder approval for the demerger of its metabolic diseases business, Autogen Research Limited, which is to be renamed Verva Pharmaceuticals Limited.
This strategic demerger allows ChemGenex to focus its resources on the advancement of its clinical-stage cancer portfolio, particularly its lead product, omacetaxine mepesuccinate (formerly known as Ceflatoninr) which is currently in phase 2/3 clinical trials for the treatment of chronic myeloid leukemia (CML).
Verva Pharmaceuticals is planning to merge with Adipogen Pharmaceuticals, a process that should be completed by December 20, 2007. Adipogen Pharmaceuticals is an early-stage pharmaceutical company focused on the development of novel therapies for the treatment of obesity. Adipogen's core technology focuses on targeting signaling molecules and enzymes responsible for fat cell formation.
Verva Pharmaceuticals will seek to list on the ASX in Q1 2008 and ChemGenex shareholders will receive one share in Verva Pharmaceuticals for every five ChemGenex Pharmaceuticals shares held at the record date (December 12, 2007). In accordance with ASX listing rules and the option agreements, existing ChemGenex option holders will not be allocated shares in Verva Pharmaceuticals unless options are exercised with funds cleared prior to the "Ex" date (December 6, 2007). After the record date the exercise price for each remaining ChemGenex option will be reduced by approximately 7 cents.
Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex, stated, "By demerging Verva Pharmaceuticals from ChemGenex, we have created two distinct companies, each with a clear focus, dedicated management and clear strategic vision."
"Through this restructuring, ChemGenex is now well-positioned to devote its resources to the development and commercialization of the anti-cancer assets in late stage clinical development, while enabling Verva Pharmaceuticals to focus on the development of novel therapeutics in the field of type 2 diabetes and obesity," Dr. Collier added.
Vince Wacher, Ph.D., Chief Executive Officer of Adipogen Pharmaceuticals, will become the Chief Executive Officer of Verva Pharmaceuticals. Several of ChemGenex's most experienced metabolic disease scientists will join the new company and Dr. Collier has accepted a Board position with Verva Pharmaceuticals.
- Verva Pharmaceuticals merger with Adipogen Pharmaceuticals on track
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced that at the company's Annual General Meeting yesterday it received shareholder approval for the demerger of its metabolic diseases business, Autogen Research Limited, which is to be renamed Verva Pharmaceuticals Limited.
This strategic demerger allows ChemGenex to focus its resources on the advancement of its clinical-stage cancer portfolio, particularly its lead product, omacetaxine mepesuccinate (formerly known as Ceflatoninr) which is currently in phase 2/3 clinical trials for the treatment of chronic myeloid leukemia (CML).
Verva Pharmaceuticals is planning to merge with Adipogen Pharmaceuticals, a process that should be completed by December 20, 2007. Adipogen Pharmaceuticals is an early-stage pharmaceutical company focused on the development of novel therapies for the treatment of obesity. Adipogen's core technology focuses on targeting signaling molecules and enzymes responsible for fat cell formation.
Verva Pharmaceuticals will seek to list on the ASX in Q1 2008 and ChemGenex shareholders will receive one share in Verva Pharmaceuticals for every five ChemGenex Pharmaceuticals shares held at the record date (December 12, 2007). In accordance with ASX listing rules and the option agreements, existing ChemGenex option holders will not be allocated shares in Verva Pharmaceuticals unless options are exercised with funds cleared prior to the "Ex" date (December 6, 2007). After the record date the exercise price for each remaining ChemGenex option will be reduced by approximately 7 cents.
Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex, stated, "By demerging Verva Pharmaceuticals from ChemGenex, we have created two distinct companies, each with a clear focus, dedicated management and clear strategic vision."
"Through this restructuring, ChemGenex is now well-positioned to devote its resources to the development and commercialization of the anti-cancer assets in late stage clinical development, while enabling Verva Pharmaceuticals to focus on the development of novel therapeutics in the field of type 2 diabetes and obesity," Dr. Collier added.
Vince Wacher, Ph.D., Chief Executive Officer of Adipogen Pharmaceuticals, will become the Chief Executive Officer of Verva Pharmaceuticals. Several of ChemGenex's most experienced metabolic disease scientists will join the new company and Dr. Collier has accepted a Board position with Verva Pharmaceuticals.